extract: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
This commit is contained in:
Teleo Agents
parent
8e3a4b891b
commit
ae677fb7e3
5 changed files with 57 additions and 1 deletions
|
|
@ -35,6 +35,12 @@ The Cell Press review characterizes GLP-1s as marking a 'system-level redefiniti
|
|||
|
||||
MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
|
||||
|
||||
Medicare-specific modeling shows $715M net savings over 10 years when comprehensive multi-indication access allows a single risk-bearing payer to capture cardiovascular ($1,512/subject), CKD ($2,074/subject), and T2D complication savings ($14,431/subject) that offset drug costs. This demonstrates the system-level vs. payer-level economics divergence: inflationary at the system level where costs and savings are distributed, but potentially cost-saving under capitated/risk-bearing arrangements.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -36,6 +36,12 @@ For value-based care models and capitated payers, this multi-organ protection cr
|
|||
|
||||
SELECT trial exploratory analysis (N=17,604, median 41.8 months) shows semaglutide reduces ALL-CAUSE hospitalizations by 10% (18.3 vs 20.4 per 100 patient-years, P<.001) and total hospital days by 11% (157.2 vs 176.2 days per 100 patient-years, P=.01). Critically, benefits extended beyond cardiovascular causes to total hospitalization burden, suggesting systemic effects across multiple organ systems.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
|
||||
|
||||
10-year Medicare modeling quantifies the multi-organ benefit: 38,950 cardiovascular events avoided (2,791 MIs, 3,000 revascularizations, 487 strokes per 100K subjects), plus CKD progression delay worth $2,074/subject and T2D complication avoidance worth $14,431/subject. The compounding effect is sufficient to produce net savings when a single payer captures all three benefit streams.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -28,6 +28,12 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist,
|
|||
- FDA indication expansion to T2D patients with CKD (2024)
|
||||
- Dialysis cost benchmark: $90K+/year per patient
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
|
||||
|
||||
Medicare modeling confirms CKD savings of $2,074 per subject treated with semaglutide, contributing to overall net savings of $715M over 10 years. While T2D complication avoidance ($14,431/subject) produces larger per-patient savings, the CKD benefit is a meaningful component of the multi-indication value proposition.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,24 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "comprehensive-glp-1-access-saves-medicare-money-when-single-payer-captures-multi-indication-benefits.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 1,
|
||||
"kept": 0,
|
||||
"fixed": 1,
|
||||
"rejected": 1,
|
||||
"fixes_applied": [
|
||||
"comprehensive-glp-1-access-saves-medicare-money-when-single-payer-captures-multi-indication-benefits.md:set_created:2026-03-16"
|
||||
],
|
||||
"rejections": [
|
||||
"comprehensive-glp-1-access-saves-medicare-money-when-single-payer-captures-multi-indication-benefits.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-16"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2025-06-01
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: paper
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, semaglutide, medicare, cost-effectiveness, cardiovascular, CKD, MASH]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-16
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -39,3 +43,13 @@ Key findings:
|
|||
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
||||
WHY ARCHIVED: This study provides the strongest evidence that the "inflationary through 2035" framing needs scope qualification — system-level vs. payer-level economics diverge when downstream savings accrue to the same entity
|
||||
EXTRACTION HINT: Focus on the distinction between system-level cost impact (inflationary) and risk-bearing payer impact (potentially cost-saving). This is the core VBC interaction.
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Medicare modeling projects 38,950 cardiovascular events avoided over 10 years with comprehensive semaglutide access
|
||||
- 6,180 deaths avoided (CV + CKD/MASH progression) in Medicare population over 10-year period
|
||||
- Per 100,000 subjects treated: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided, 115 CV deaths avoided
|
||||
- Average per-subject lifetime semaglutide treatment costs: $47,353
|
||||
- T2D-related Medicare savings: ~$892 million over 10 years
|
||||
- Obesity-related Medicare costs: ~$205 million over 10 years
|
||||
- MASH-related Medicare savings: ~$28 million over 10 years
|
||||
|
|
|
|||
Loading…
Reference in a new issue